What does Grail do and what are its main business segments?

Did Grail beat or miss consensus estimates last quarter?

What is Grail's gross profit margin?

What factors drove the changes in Grail's revenue and profit?

What were the key takeaways from Grail’s earnings call?

What is the revenue and EPS growth rate for Grail year over year?

What is Grail's latest dividend and current dividend yield?

What guidance did Grail's management provide for the next earnings period?

- **NHS-Galleri Trial Successes**: 20% reduction in Stage IV cancers in later rounds, fourfold increase in cancer detection rate, and no serious safety concerns.
- **Commercial Momentum**: 36% test volume growth in 2025, 26% revenue growth, and 30% prescriber base expansion.
- **FDA PMA Submission**: Completed in January 2026, with 12-month review period expected.
- **Financial Strength**: $904.4 million cash runway, 2026 guidance: Galleri sales growth 22-32%, cash burn ≤$300 million.

**【CEO Summary Section】**
- Announced top-line results from the NHS-Galleri trial, showing a 20% reduction in Stage IV cancers in the second and third screening rounds, despite missing the primary endpoint of statistically significant combined Stage III and IV reduction.
- U.S. Galleri test volume grew 36% to 185,000 tests in 2025, with revenue up 26%, driven by a 30% increase in prescriber base to 17,000 providers.
- Completed PMA submission to the FDA for Galleri, with a 12-month review period expected.
- New federal law establishes Medicare coverage pathway for FDA-approved multi-cancer early detection (MCED) tests.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $43.6 million (14% YoY growth), with full-year 2025 revenue of $147.2 million (17% YoY growth).
- Non-GAAP adjusted gross profit: $23.1 million (Q4) and $73.6 million (full-year), up 29% and 27% YoY, driven by scale efficiencies.
- Net loss for 2025: $408.4 million (80% improvement YoY), with cash position of $904.4 million.
- Reiterated 2026 guidance: Galleri sales growth of 22-32%, cash burn ≤$300 million.

**【Q&A Key Highlights】**
- **FDA Approval Probability**: Management believes the PMA submission, including PATHFINDER 2 and NHS-Galleri prevalent round data, remains on track for approval, with FDA focused on clinical performance and safety.
- **International Expansion**: Positive trial results will support discussions with NHS and other countries, with plans to extend NHS-Galleri follow-up by 6-12 months.
- **Medicare Coverage**: Upon FDA approval, CMS will initiate a National Coverage Analysis, with Galleri's robust data package expected to support coverage.
- **Sales Force Expansion**: Despite missing the primary endpoint, the company is expanding its U.S. sales force due to strong demand and clinical evidence of Galleri's benefits (e.g., fourfold cancer detection rate vs. standard care).

GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q3 2025 U.S. Galleri revenue up 28% YoY, with 45,000 tests sold and 420,000+ cumulative commercial tests.
- **Strategic Expansion**: Samsung $110M investment and Canadian launch drive international growth, with FDA PMA submission in Q1 2026.
- **Clinical Excellence**: PATHFINDER 2 study shows 7x cancer detection rate vs. standard screening, 61.6% PPV, and 99.6% specificity.
- **Financial Strength**: $850M cash, 55% non-GAAP gross margin, and $290M 2025 cash burn (50% YoY decline).

**【CEO Summary Section】**
- Q3 2025 revenue grew 26% YoY to $36.2 million, with U.S. Galleri revenue up 28% YoY. Galleri test volumes reached 45,000 in Q3, with cumulative commercial tests exceeding 420,000.
- Strategic collaborations include a $110 million equity investment from Samsung for Asian market expansion and Canadian launch via Medcan partnership.
- PATHFINDER 2 study showed Galleri detected 7x more cancers than standard screening, with 61.6% PPV and 99.6% specificity. FDA PMA submission expected in Q1 2026.

**【CFO Financial Commentary】**
- Non-GAAP adjusted gross margin improved to 55% (vs. 41% Q3 2024), driven by lower variable costs and higher lab efficiency.
- Cash position strengthened to $850 million post-$325 million private placement, with updated full-year cash burn guidance of $290 million (50% YoY decline).
- U.S. Galleri revenue growth refined to mid-20% range for 2025, reflecting seasonal trends and provider channel momentum.

**【Q&A Key Highlights】**
- FDA PMA timeline accelerated to Q1 2026 due to regulatory engagement confidence.
- $150-off promotion boosted Q3 demand elasticity, with ASP impact mitigated by volume growth.
- Samsung investment and NHS Galleri data will support international expansion and FDA submissions.
- Cost of screening revenue per test declined 28% YoY, driven by platform automation and scale economies.

GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue $35.5M (+11% YoY), U.S. Galleri up 21% YoY. 2025 cash burn guidance reduced to ≤$310M (40% YoY decrease).
- **Clinical Success**: PATHFINDER 2 shows >2x cancer detection vs. standard screening, PPV >43%, 99.5% specificity. NHS Galleri trial demonstrates higher PPV in asymptomatic adults.
- **Strategic Momentum**: 45,000 Q2 tests sold, 25% repeat rate. FDA PMA submission expected H1 2026, with approval process 12-18 months. International expansion driven by NHS Galleri trial results (mid-2026).

**【Management Opening Remarks】**
- CEO Bob Ragusa highlighted Q2 2025 progress, including 45,000 Galleri tests sold (total 370,000+ since launch) and partnerships with Rush University and Everlywell. PATHFINDER 2 registrational study results show improved PPV and cancer detection rates, with full data to be presented at ESMO 2025. The company remains on track for FDA PMA submission in H1 2026 and NHS Galleri clinical utility data mid-2026.
- CFO Aaron Freidin reported Q2 revenue of $35.5M (up 11% YoY), with U.S. Galleri revenue growing 21% YoY. Net loss improved to $114M (93% YoY reduction), and cash burn guidance updated to ≤$310M for 2025 (40% YoY decrease). Cash runway extends to 2028.

**【CEO & Clinical Leadership Commentary】**
- PATHFINDER 2 results: 25,000-patient analysis shows >2x additional cancer detection vs. standard screening, PPV >43% (vs. 43% in PATHFINDER 1), and 99.5% specificity. NHS Galleri trial demonstrates higher PPV in asymptomatic adults. Galleri's methylation-based approach maintains high accuracy across 450K+ commercial tests, with 25% repeat testing rate.
- Strategic focus: FDA approval, reimbursement expansion, and international partnerships. NHS Galleri trial results will inform U.K. deployment, while U.S. partnerships (e.g., Quest Diagnostics) drive 7% of Q2 orders via integrated platforms.

**【Q&A Highlights】**
- **Cash Management**: 2025 cash burn guidance reduced to ≤$310M (from $320M), driven by revenue growth and automation scale-up. 2024 cash burn was $518M.
- **FDA Timeline**: PMA submission expected H1 2026, with approval process estimated at 12-18 months. FDA focuses on clinical validation, not utility, for approval.
- **International Expansion**: NHS Galleri trial results (mid-2026) will serve as evidence for global negotiations. Quest integration shows higher prescriber engagement (500+ providers via Quest in 2025).
- **Repeat Testing**: 25% of Q2 tests were repeats, up from 20% in Q1. Blood-based testing convenience and clinical validation drive adherence.


GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 19% YoY to $31.8M, driven by 37,000+ Galleri tests sold.
- **Clinical Momentum**: NHS-Galleri trial shows PPV >43%, with full 3-year results expected mid-2026.
- **Cash Efficiency**: 2025 cash burn target ≤$320M (40%+ reduction vs. 2024), supporting FDA PMA submission in H1 2026.
- **Market Leadership**: 20% repeat testing rate, >325,000 prescriptions, and $700M+ cash runway reinforce competitive position.


**【CEO Opening Remarks】**
- Q1 2025 revenue reached $31.8 million, up 19% YoY, driven by 37,000+ Galleri tests sold.
- Galleri now accounts for >325,000 prescriptions since launch in 2021, with 20% repeat testing rate.
- Key partnerships: Athena Health integration for streamlined ordering, TRICARE coverage on track, and Israel launch via OncoTest.
- New 'Generation Possible' campaign with Kate Walsh to boost public awareness.

**【CFO Financial Update】**
- Q1 2025 net loss: $106.2 million (51% improvement YoY).
- Non-GAAP adjusted gross profit: $14.3 million (19% YoY growth).
- Cash position: $677.9 million, with 2025 cash burn target ≤$320 million (40%+ reduction vs. 2024).
- Enhanced Galleri version launched Q4 2024, driving variable COGS improvements.

**【Clinical & Trial Updates】**
- NHS-Galleri trial: First round PPV >43% (PATHFINDER benchmark), 99.5% specificity, 88% CSO accuracy.
- PATHFINDER 2 interim data (25,000 participants) expected late 2025.
- FDA PMA submission planned H1 2026 with 3-year NHS-Galleri results.
- Mayo Clinic study: 73% PPV in real-world setting, validating clinical utility.

**【Q&A Highlights】**
- **Cost Management**: Q1 2025 cash burn ~$90 million (includes one-time bonus payout); 2025 target of $320M reflects margin expansion.
- **Competitive Landscape**: Competitors' MCED launches unlikely to impact OpEx; GRAIL maintains market leadership with >$700M cash runway.
- **NHS Conversations**: UK government awaiting full 3-year trial results (mid-2026) before deciding on national rollout.
- **ASP & Economics**: Annual testing assumed in ASP modeling; health economics favorable vs. single-cancer screening alternatives.


GRAIL (GRAL)-13 May 25-2025 Q1 Earnings call transcript

- **Galleri Growth Accelerates**: 45% YoY revenue to $137M, enhanced test version slashes COGS
- **Partnerships Expand Access**: Quest integration enables 500K+ physician orders, TRICARE coverage for high-risk patients
- **Financial Efficiency**: 2024 cash burn down 48%, 2025 guidance for $320M (-40% YoY)
- **FDA Milestone Visibility**: Modular PMA submission in H1 2026, registrational studies nearing completion
- **Legislative Momentum**: Bipartisan MCED bill reintroduced with 2028 reimbursement target

**【CEO Opening Remarks】**
- GRAIL achieved significant milestones in 2024, including separation from Illumina, FDA modular PMA submission for Galleri, and U.S. Galleri revenue growth of 45% YoY to $137 million.
- Launched enhanced Galleri version with 4x sample throughput, reduced COGS, and full lab automation, enabling scalability without additional CapEx.
- Integrated with Quest Diagnostics for easier physician ordering, expanding access to 7,400 locations nationwide.
- TRICARE coverage secured for high-risk patients, pending carrier implementation.

**【President Joshua Ofman’s Technical Update】**
- New Galleri version features:
  - 4x sample processing efficiency via reduced panel size
  - Fully automated workflow eliminating manual steps
  - COGS improvements as scale increases
- 2024 registrational studies (NHS-Galleri, PATHFINDER 2) nearing completion with FDA submission in H1 2026.
- MCED legislation reintroduced with bipartisan support, targeting 2028-2029 reimbursement timelines aligned with stool-based tests.

**【CFO Aaron Freidin’s Financial Review】**
- Q4 2024 Results:
  - Revenue: $38.3M (+26% YoY), with $31.6M screening (+39% YoY) and $6.7M dev services
  - Net loss: $97.1M (48% YoY improvement)
  - Adjusted EBITDA: -$84M (32% YoY improvement)
  - Cash: $766.8M
- Full Year 2024:
  - Revenue: $125.6M (+35% YoY)
  - Adjusted EBITDA: -$483.5M (8% YoY improvement)
- 2025 Guidance: Cash burn ≤$320M (-40% YoY), extending runway to 2028.

**【Q&A Key Highlights】**
- **Quest/Tricare Impact**: 2025 guidance incorporates current collaboration plans; upside potential if demand elasticity materializes
- **Legislation Timeline**: 2028 reimbursement target aligns with stool-based tests; no change to 2025 financial outlook
- **PATHFINDER 2 Expectations**: Safety and diagnostic performance metrics will drive FDA submission
- **Cash Flexibility**: 2028 runway includes buffer for regulatory delays
- **AI Synergies**: Long-term opportunity with AI in early cancer detection, no near-term financial impact

Actual	-51.055	-3.94	-2.89	-3.1	-3.18	-2.46	-2.44
Forecast		-6.43	-4.9733	-3.9867	-3.5675	-3.365	-2.7
Surprise	0.00%	+38.72%	+41.89%	+22.24%	+10.86%	+26.89%	+9.63%

Actual	31.98M	28.65M	38.25M	31.84M	35.54M	36.19M	43.60M
Forecast	--	33.90M	34.40M	35.20M	36.90M	34.60M	43.58M
Surprise	0.00%	-15.48%	+11.20%	-9.55%	-3.67%	+4.61%	+0.04%

GRAL

GRAL fundamentals

GRAL Q4 2025 Earnings

Earnings Call

You can ask Aime

GRAL

GRAL fundamentals

GRAL Q4 2025 Earnings

Earnings Call

GRAL Earnings Call Summary for Q4/20255:00 PM on Feb 19, 2026

GRAL Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

GRAL Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

GRAL Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

GRAL Earnings Call Summary for Q4/20244:30 PM on Feb 20, 2025

You can ask Aime